A randomised open-label trial to assess change in respiratory function for people with cystic fibrosis (pwCF) established on triple combination therapy (Kaftrio™) after rationalisation of nebulised mucoactive therapies (the CF STORM trial)
Latest Information Update: 02 Aug 2024
At a glance
- Drugs Elexacaftor/ivacaftor/tezacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Acronyms CF STORM
- 02 Aug 2024 Status changed from recruiting to completed.
- 01 Sep 2023 Planned End Date changed from 30 Sep 2023 to 31 Jul 2024.
- 01 Sep 2023 Recruitment completion is expected on 31 Jul 2024, according to ISRCTN: Current Controlled Trials.